Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism

Eur Respir J. 2017 May 25;49(5):1601980. doi: 10.1183/13993003.01980-2016. Print 2017 May.

Abstract

The impact of residual pulmonary obstruction on the outcome of patients with pulmonary embolism is uncertain.We recruited 647 consecutive symptomatic patients with a first episode of pulmonary embolism, with or without concomitant deep venous thrombosis. They received conventional anticoagulation, were assessed for residual pulmonary obstruction through perfusion lung scanning after 6 months and then were followed up for up to 3 years. Recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension were assessed according to widely accepted criteria.Residual pulmonary obstruction was detected in 324 patients (50.1%, 95% CI 46.2-54.0%). Patients with residual pulmonary obstruction were more likely to be older and to have an unprovoked episode. After a 3-year follow-up, recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension developed in 34 out of the 324 patients (10.5%) with residual pulmonary obstruction and in 15 out of the 323 patients (4.6%) without residual pulmonary obstruction, leading to an adjusted hazard ratio of 2.26 (95% CI 1.23-4.16).Residual pulmonary obstruction, as detected with perfusion lung scanning at 6 months after a first episode of pulmonary embolism, is an independent predictor of recurrent venous thromboembolism and/or chronic thromboembolic pulmonary hypertension.

Trial registration: ClinicalTrials.gov NCT01781858.

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Hypertension, Pulmonary / therapy
  • Incidence
  • Lung / diagnostic imaging
  • Lung Diseases / complications
  • Lung Diseases / drug therapy*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Perfusion
  • Proportional Hazards Models
  • Prospective Studies
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / drug therapy*
  • Recurrence
  • Risk Factors
  • Secondary Prevention
  • Treatment Outcome
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / drug therapy
  • Venous Thrombosis / complications

Substances

  • Anticoagulants

Associated data

  • ClinicalTrials.gov/NCT01781858